Organogenesis Holdings Inc.
NASDAQ:ORGO · NASDAQ Capital Market
+$0.08 today
Vol 0.64M · Avg 1.49M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ORGO · Revenue to Net Income
Key Ratios
Analysis
$513.6M of revenue converted into -$284.0K of net income for the selected period. Gross margin is 56.0% and net margin is -31.6%, showing how much revenue survives after costs and taxes. EPS is $-0.16, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $563.0M +16.8% | $482.0M +11.3% | $433.1M -3.9% | $450.9M -3.5% | $467.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $137.5M +18.8% | $115.7M +8.7% | $106.5M +1.4% | $105.0M -8.0% | $114.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $425.5M +16.2% | $366.3M +12.1% | $326.7M -5.6% | $345.9M -2.1% | $353.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 75.6% -0.4pp | 76.0% +0.6pp | 75.4% -1.3pp | 76.7% +1.1pp | 75.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $44.5M -11.4% | $50.3M +13.3% | $44.4M +11.6% | $39.8M +29.3% | $30.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $326.2M +10.8% | $294.5M +9.2% | $269.8M -5.0% | $283.8M +13.4% | $250.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $369.6M +0.6% | $367.6M +17.0% | $314.1M -2.9% | $323.6M +15.2% | $280.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $26.9M +58.2% | $17.0M -27.4% | $23.4M +30.0% | $18.0M +8.1% | $16.7M | $374.2M | $1.2B | $631.8M |
| EBITDA | $73.9M +368.9% | $15.8M -56.3% | $36.0M -10.6% | $40.3M -53.7% | $87.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 13.1% +9.9pp | 3.3% -5.0pp | 8.3% -0.6pp | 8.9% -9.7pp | 18.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | $55.9M +4454.6% | -$1.3M -110.2% | $12.5M -43.8% | $22.3M -69.1% | $72.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 9.9% +10.2pp | -0.3% -3.2pp | 2.9% -2.1pp | 4.9% -10.5pp | 15.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.3M | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $1.5M -29.5% | $2.2M +9.0% | $2.0M -72.2% | $7.2M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$8.9M -483.9% | -$1.5M +28.6% | -$2.1M -5.5% | -$2.0M +77.9% | -$9.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $47.0M +1773.3% | -$2.8M -127.0% | $10.4M -48.8% | $20.3M -67.9% | $63.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 8.3% +8.9pp | -0.6% -3.0pp | 2.4% -2.1pp | 4.5% -9.0pp | 13.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $9.9M +370.9% | -$3.7M -167.3% | $5.4M +14.7% | $4.8M +115.3% | -$31.1M | $1.3B | -$1.6B | $745.2M |
| Net Income | $37.0M +4201.0% | $861.0K -82.6% | $4.9M -68.2% | $15.5M -83.5% | $94.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | 6.6% +6.4pp | 0.2% -1.0pp | 1.1% -2.3pp | 3.4% -16.7pp | 20.2% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $0 +2353.5% | -$0 -118.8% | $0 -68.6% | $0 -83.6% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $0 +1600.0% | -$0 -126.8% | $0 -68.9% | $0 -82.9% | $1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $126.7M -3.7% | $131.7M +0.3% | $131.2M +0.9% | $130.1M +1.4% | $128.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $130.2M -1.1% | $131.7M -0.8% | $132.7M +0.3% | $132.4M -1.0% | $133.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Esperion Therapeutics, Inc.
NASDAQ:ESPR
$659.07M
AngioDynamics, Inc.
NASDAQ:ANGO
$494.79M
Varex Imaging Corporation
NASDAQ:VREX
$444.14M
Monopar Therapeutics Inc.
NASDAQ:MNPR
$441.20M
Evolus, Inc.
NASDAQ:EOLS
$436.95M
Emergent BioSolutions Inc.
NYSE:EBS
$410.71M
SNDL Inc.
NASDAQ:SNDL
$369.29M
SIGA Technologies, Inc.
NASDAQ:SIGA
$308.06M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$281.99M
Bicycle Therapeutics plc
NASDAQ:BCYC
$277.23M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ORGO generate?
Organogenesis Holdings Inc. (ORGO) reported $563.03M of revenue in fiscal 2025.
Is ORGO profitable?
Organogenesis Holdings Inc. (ORGO) reported $37.03M of net income, with a net margin of 6.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.